| Date | Title | Description | Source |
| 19.03.2024 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Yea... | – On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 –
– Expect to Report Final ... | einpresswi... |
| 13.03.2024 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full ... | BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: C... | einpresswi... |
| 07.03.2024 | Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Conc... | - | globenewsw... |
| 06.03.2024 | Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R... | - | globenewsw... |
| 08.01.2024 | Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Mini... | BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | einpresswi... |
| 09.08.2023 | Cyclacel Pharmaceuticals Reports Second Quarter Financial Re... | - Key Catalysts ahead with Multiple Value Generating Readouts-
- Expects to Release Phase 1/2 Data w... | einpresswi... |
| 03.08.2023 | Cyclacel Pharmaceuticals to Release Second Quarter 2023 Fina... | BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | einpresswi... |
| 11.05.2023 | Cyclacel Pharmaceuticals Reports First Quarter Financial Res... | /EIN News/ -- - Key Catalysts ahead with multiple Value Generating Readouts -
- Expects to Report Ph... | einpresswi... |
| 06.03.2023 | Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Yea... | /EIN News/ -- - On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report In... | einpresswi... |
| 05.01.2023 | Cyclacel Pharmaceuticals Reviews 2022 Achievements and Annou... | /EIN News/ -- – Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral F... | einpresswi... |
| 03.11.2022 | Cyclacel Pharmaceuticals to Release Third Quarter 2022 Finan... | /EIN News/ -- BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, In... | einpresswi... |
| 26.10.2022 | Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinica... | Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor... | einpresswi... |
| 26.10.2022 | Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinica... | BERKELEY HEIGHTS, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | globenewsw... |
| 24.10.2022 | Cyclacel Hosting Research & Development Day | -Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the ... | globenewsw... |
| 24.10.2022 | Cyclacel Hosting Research & Development Day | /EIN News/ -- -Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CY... | einpresswi... |
| 13.10.2022 | Cyclacel Pharmaceuticals To Present Preliminary Data From Th... | BERKELEY HEIGHTS, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | globenewsw... |
| 21.09.2022 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalman... | BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: C... | globenewsw... |
| 10.08.2022 | Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financi... | - Oral fadraciclib demonstrated good tolerability with continuous dosing;
anticipate entering Phase ... | globenewsw... |
| 03.08.2022 | Cyclacel Pharmaceuticals to Release Second Quarter 2022 Fina... | BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | globenewsw... |
| 30.06.2022 | Cyclacel Pharmaceuticals Achieves Key Business Objectives in... | - Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors -
- No Dose ... | globenewsw... |
| 11.05.2022 | Cyclacel Pharmaceuticals Reports First Quarter 2022 Financia... | - Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering P... | globenewsw... |
| 04.05.2022 | Cyclacel Pharmaceuticals to Release First Quarter 2022 Finan... | BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYC... | globenewsw... |
| 19.04.2022 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Stud... | BERKELEY HEIGHTS, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: C... | globenewsw... |
| 12.04.2022 | Cyclacel Pharmaceuticals Announces Publication Confirming Fa... | -New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia-
-Remarkable ... | globenewsw... |
| 28.03.2022 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Yea... | -Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 202... | globenewsw... |
| 22.03.2022 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full ... | BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: C... | globenewsw... |
| 07.02.2022 | Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO &... | BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | globenewsw... |
| 06.01.2022 | Cyclacel Pharmaceuticals Reviews 2021 Achievements And Annou... | – Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –
... | globenewsw... |
| 06.01.2022 | Cyclacel Pharmaceuticals Reviews 2021 Achievements And Annou... | – Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –
... | marketscre... |
| 23.12.2021 | Cyclacel Pharmaceuticals to Participate in Biotech Showcase ... | BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | globenewsw... |
| 10.11.2021 | Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financia... | - Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia -
- Cash Runway to Early ... | globenewsw... |
| 05.11.2021 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Stud... | BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | marketscre... |
| 05.11.2021 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Stud... | Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations i... | marketscre... |
| 05.11.2021 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Stud... | BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | globenewsw... |
| 29.10.2021 | Cyclacel Pharmaceuticals to Release Third Quarter 2021 Finan... | BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | globenewsw... |
| 11.08.2021 | Cyclacel Pharmaceuticals Reports Second Quarter 2021 Financi... | - Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib -
- Additional Phase 1/2 Tr... | marketscre... |
| 13.07.2021 | Cyclacel Announces Dosing of First Patient in Phase 1/2 Stud... | BERKELEY HEIGHTS, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | marketscre... |
| 15.03.2021 | Cyclacel to Present at the Oppenheimer 31st Annual Healthcar... | BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: C... | globenewsw... |
| 12.03.2021 | Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten ... | BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: C... | globenewsw... |
| 26.02.2021 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Yea... | BERKELEY HEIGHTS, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | marketscre... |
| 19.02.2021 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full ... | BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CY... | globenewsw... |
| 11.01.2021 | CYCLACEL PHARMACEUTICALS, INC.
Cyclacel Pharmaceuticals Rev... | – Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–
– App... | marketscre... |
| 04.05.2012 | Cancer drug developer Cyclacel raising $3 million | Research and development costs for the drug increased by 44 percent, or $2.8 million, to $9.2 millio... | medcitynew... |
| - | Cancer drug developer Cyclacel raising $3 million | Cyclacel Pharmaceuticals (NASDAQ:CYCC), a cancer drug developer, is raising $3 million for litigatio... | medcitynew... |
